Ascendis Pharma A/S

HELLERUP, G7 · Biotech · Private

TransCon technology platform for sustained-release therapeutic delivery

New patent ·
Claim this profile

Follows are private to you and power your alerts

Updated · ascendispharma.com

Sector
Biotech
Headquarters
HELLERUP, G7
Latest Form D
$60M, Dec 2014
Total capital
$60M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$60M
1 Form D · last Dec 2014
143 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
20
20 pending · first 2023
Rank in peer group#52 of 1449

Capital timeline

2014FEDERAL ↑EQUITY ↓Cumulative $60M1st Form D$60M
2014FEDERAL ↑EQUITY ↓Cumulative $60M1st Form D$60M

Latest events

  • Private capital raisedForm D · SEC · 1st filing$60M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#52 · top 4%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Albert Wolff ChaDirectorNamed in SEC Form D filings
  • Edwin Wolff de GraafDirectorNamed in SEC Form D filings
  • Grethe Wolff RasmussenExecutive OfficerNamed in SEC Form D filings
  • Harald Wolff RauExecutive OfficerNamed in SEC Form D filings
  • James Wolff HealyDirectorNamed in SEC Form D filings
  • Jan M?ller MikkelsenExecutive Officer, DirectorNamed in SEC Form D filings
Show all 14 people
  • Jonathan Wolff SilversteinDirectorNamed in SEC Form D filings
  • Lotte Wolff S?nderbjergExecutive OfficerNamed in SEC Form D filings
  • Martin Wolff AusterExecutive OfficerNamed in SEC Form D filings
  • Martin Wolff OlinDirectorNamed in SEC Form D filings
  • Michael Wolff JensenExecutive Officer, DirectorNamed in SEC Form D filings
  • Michael Wolff MayerDirectorNamed in SEC Form D filings
  • Rafa?le Wolff TordjmanDirectorNamed in SEC Form D filings
  • Thomas Wolff SolowayExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 20 granted of 40
Show all 40 patent records

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .